As of December 31, 2019, LEXINGTON BIOSCIENCES INC carries a market capitalization of 56,045.23, placing it among publicly traded companies globally. Its enterprise value stands at 695,565.74, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 56,045.23 |
| Enterprise Value | 695,565.74 |
As of December 31, 2019, LEXINGTON BIOSCIENCES INC has 3.79M shares outstanding.
| Shares Outstanding | 3.79M |
These figures are as of December 31, 2019.
| PB Ratio | -0.07 |
| P/TBV Ratio | -0.07 |
| P/FCF Ratio | -0.35 |
| P/OCF Ratio | -0.35 |
As of December 31, 2019, LEXINGTON BIOSCIENCES INC maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | -81.13 |
| Debt / EBITDA | -1.58 |
These figures cover the twelve months ended December 31, 2019. Return on assets (ROA) is negative at -2,113.64, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -2,113.64 |
As of the close on October 23, 2026, LEXINGTON BIOSCIENCES INC's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.
| 52-Week Price Change | -99.00% |
| 200-Day Moving Average | 0.01 |
Over the twelve months ended December 31, 2019, LEXINGTON BIOSCIENCES INC generated - - in revenue and converted that into -977,603.61 in net income, yielding earnings per share of -0.26. EBITDA reached -410,763.20, while operating income came in at -410,763.20.
| Operating Income | -410,763.20 |
| Pretax Income | -977,603.61 |
| Net Income | -977,603.61 |
| EBITDA | -410,763.20 |
| EBIT | -410,763.20 |
| Earnings Per Share (EPS) | -0.26 |
As of December 31, 2019, LEXINGTON BIOSCIENCES INC holds 9,873.20 in cash and equivalents against 649,393.70 in total debt, resulting in a net debt position of 639,520.51. Total book value stands at -800,393.42, with working capital of -800,393.42 providing operational flexibility.
| Cash & Cash Equivalents | 9,873.20 |
| Total Debt | 649,393.70 |
| Net Debt | 639,520.51 |
| Equity (Book Value) | -800,393.42 |
| Book Value Per Share | -0.21 |
| Working Capital | -800,393.42 |
LEXINGTON BIOSCIENCES INC produced -161,889.18 in operating cash flow over the twelve months ended December 31, 2019.
| Operating Cash Flow | -161,889.18 |
| Free Cash Flow | -161,889.18 |
| FCF Per Share | -0.04 |
These figures cover the twelve months ended December 31, 2019. Free cash flow yield is negative at -289.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -159.03, meaning LEXINGTON BIOSCIENCES INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -159.03 |
| FCF Yield | -289.03 |
LEXINGTON BIOSCIENCES INC's most recent stock split took place on April 26, 2019 with a 10:1 split ratio.
| Last Split Date | 4/26/2019 |
| Split Ratio | 10:1 |
As of December 31, 2019, LEXINGTON BIOSCIENCES INC has an Altman Z-Score of -1,238.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1,238.81 |
Already premium?